CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-12 | Sabag Mark See "Remarks" | Option exercise | +44,710 | $34.90 | $1.6M | 125,470 |
| 2026-11-12 | Sabag Mark See "Remarks" | Sale | −44,710 | $44.14 | $2.0M | 80,760 |
| 2026-11-12 | Sabag Mark See "Remarks" | Option exercise · Stock Options (right to buy) | −44,710 | 0 | ||
| 2026-11-11 | Daniell Richard EVP, Europe Commercial | Option exercise | +20,003 | $34.70 | $694K | 75,758 |
| 2026-11-11 | Daniell Richard EVP, Europe Commercial | Sale | −20,003 | $42.80 | $856K | 55,755 |
| 2026-11-11 | Daniell Richard EVP, Europe Commercial | Option exercise · Stock Options (right to buy) | −20,003 | 0 | ||
| 2026-11-10 | Francis Richard D President and CEO | Sale 10b5-1 | −250,000 | $42.24 | $10.6M | 927,529 |
| 2026-11-10 | Bergwerk Dov Interim Chief Legal Officer | Grant or award · Restricted Share Units | +9,433 | 9,433 | ||
| 2026-11-10 | BRAILER DAVID J Director | Grant or award · Restricted Share Units | +3,326 | 3,326 | ||
| 2026-11-09 | Daniell Richard EVP, Europe Commercial | Option exercise | +25,000 | $34.70 | $868K | 80,755 |
| 2026-11-09 | Daniell Richard EVP, Europe Commercial | Sale | −25,000 | $42.91 | $1.1M | 55,755 |
| 2026-11-09 | Daniell Richard EVP, Europe Commercial | Option exercise · Stock Options (right to buy) | −25,000 | 20,003 | ||
| 2026-11-09 | Weiss Amir Chief Accounting Officer | Option exercise | +7,755 | $34.70 | $269K | 20,826 |
| 2026-11-09 | Weiss Amir Chief Accounting Officer | Sale | −662 | $43.15 | $29K | 20,164 |
| 2026-11-09 | Weiss Amir Chief Accounting Officer | Sale | −7,093 | $43.03 | $305K | 13,071 |
| 2026-11-09 | Weiss Amir Chief Accounting Officer | Sale | −9,534 | $43.03 | $410K | 3,537 |
| 2026-11-09 | Weiss Amir Chief Accounting Officer | Option exercise · Stock Options (right to buy) | −7,755 | 0 | ||
| 2026-11-05 | Sabag Mark See "Remarks" | Option exercise | +46,000 | $34.90 | $1.6M | 126,760 |
| 2026-11-05 | Sabag Mark See "Remarks" | Sale | −46,000 | $41.93 | $1.9M | 80,760 |
| 2026-11-05 | Sabag Mark See "Remarks" | Option exercise · Stock Options (right to buy) | −46,000 | 44,710 |
Page 1 of 64 · 1,279 trades